Intestinal Research

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease

Cheng-Chun Ji, Shota Takano

Intest Res. 2017;15(2):182-186. Published online 2017 Apr 27 DOI: https://doi.org/10.5217/ir.2017.15.2.182

Citations to this article as recorded by

Choosing Therapy for Moderate to Severe Crohn’s Disease

Malcolm Irani, Bincy Abraham

Journal of the Canadian Association of Gastroenterology.2024; 7(1): 1. CrossRef

The use of core descriptors from the ENiGMA code study in recent literature: a systematic review

Saher‐Zahra Khan, Andrea Arline, Kate M. Williams, Matthew J. Lee, Emily Steinhagen, Sharon L. Stein

Colorectal Disease.2024; 26(3): 428. CrossRef

Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021

Hiroshi Nakase, Motohiro Esaki, Fumihito Hirai, Taku Kobayashi, Katsuyoshi Matsuoka, Minoru Matsuura, Makoto Naganuma, Masayuki Saruta, Kiichiro Tsuchiya, Motoi Uchino, Kenji Watanabe, Tadakazu Hisamatsu, Akira Andoh, Shigeki Bamba, Motohiro Esaki, Mikihi

Journal of Gastroenterology.2023; 58(4): 313. CrossRef

Perianal fistulas in Crohn's disease (review)

I. S. Anosov, B. A. Nanaeva, A. V. Vardanyan, M. A. Zakharov

Koloproktologia.2023; 22(1): 128. CrossRef

Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

Laura Maas, Ruiyi Gao, Vivy Cusumano, Ellen Spartz, Reezwana Chowdhury, Mahesh Krishna, Mark Lazarev, Joanna Melia, Florin Selaru, Sowmya Sharma, Berkeley Limketkai, Alyssa Parian

Digestive Diseases and Sciences.2023; 68(10): 3994. CrossRef

Management of Perianal Fistulizing Crohn’s Disease

Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen, Ajit Sood

Inflammatory Bowel Diseases.2023;[Epub] CrossRef

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?

Gustavo Drügg Hahn, Petra Anna Golovics, Panu Wetwittayakhlang, Alex Al Khoury, Talat Bessissow, Peter Laszlo Lakatos

Biomedicines.2022; 10(4): 749. CrossRef

The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials

Panu Wetwittayakhlang, Alex Al Khoury, Gustavo Drügg Hahn, Peter Laszlo Lakatos

Journal of Clinical Medicine.2022; 11(11): 3045. CrossRef

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis

Hua-Hua Yang, Yi Huang, Xu-Chun Zhou, Ruo-Nan Wang

World Journal of Clinical Cases.2022; 10(18): 6091. CrossRef

An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases

Tao Luo, Yile Wang, Hailin Tang, Fei Zhou, Ying Chen, Bing Pei, Jinke Wang

Journal of Inflammation Research.2022; Volume 15: 3447. CrossRef

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease

Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon

Gut and Liver.2021; 15(1): 92. CrossRef

Predictors of reoperation for perianal fistula in Crohn's disease

Kwangwoo Nam, Won Beom Jung, Seung Bum Lee, Jae Seung Soh, Song Soo Yang, Seok Won Jung

Journal of Digestive Diseases.2021; 22(6): 334. CrossRef

Managing Complex Perianal Fistulizing Disease

Karina E. Pedersen, Amy L. Lightner

Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 890. CrossRef

Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn’s disease treated with antitumor necrosis factor-alpha agents based on Parks’ classification

Nahla Azzam, Othman Alharbi, Majid Almadi, Abdulrahman Aljebreen, Turki AlAmeel, Mohammed Alabbas, Salman Bahammam, Ahmed Bashmail, Yasser Alomar, Mahmoud Mosli

European Journal of Gastroenterology & Hepatology.2020; 32(2): 187. CrossRef

Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy

Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon

The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef

Characteristics of biological therapy in pediatric patients with Crohn’s disease

Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki, Gabor Veres

Expert Opinion on Biological Therapy.2019; 19(3): 181. CrossRef

Endorectal Advancement Flaps for Perianal Fistulae in Crohn’s Disease: Careful Patient Selection Leads to Optimal Outcomes

Michelle T. Roper, Stephen M. Trinidad, Sonia L. Ramamoorthy, Lisa A. Parry, Nicole E. Lopez, Sergey Khaitov, Randolph Steinhagen, Samuel G. Eisenstein

Journal of Gastrointestinal Surgery.2019; 23(11): 2277. CrossRef

Maneuvering Clinical Pathways for Crohn’s Disease

Thomas X. Lu, Russell D. Cohen

Current Gastroenterology Reports.2019;[Epub] CrossRef

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia

Journal of Gastroenterology and Hepatology.2019; 34(8): 1296. CrossRef

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia

Intestinal Research.2019; 17(3): 285. CrossRef

Long‐term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first‐line biologics

Toshihiro Inokuchi, Sakuma Takahashi, Sakiko Hiraoka, Tatsuya Toyokawa, Shinjiro Takagi, Koji Takemoto, Jiro Miyaike, Tsuyoshi Fujimoto, Reiji Higashi, Yuki Morito, Toru Nawa, Seiyuu Suzuki, Mamoru Nishimura, Masafumi Inoue, Jun Kato, Hiroyuki Okada

Journal of Gastroenterology and Hepatology.2019; 34(8): 1329. CrossRef

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?

Jong Pil Im

Intestinal Research.2017; 15(2): 147. CrossRef